Serum exocrine pancreas enzymes are biomarkers of immunotherapy response in new-onset type 1 diabetes

Serum exocrine pancreas enzymes are biomarkers of immunotherapy response in new-onset type 1 diabetes

IntroductionThe immune-mediated destruction of insulin-producing β-cells characterizes type 1 diabetes. Nevertheless, exocrine pancreatic enzymes, including amylase, lipase, and trypsin, are also significantly reduced in type 1 diabetes. With an immunotherapy now approved to treat early-stage type 1...

Full description

Saved in:
Bibliographic Details
Main Authors: Brittany Sorensen Bruggeman, Savanna Gornisiewicz, Rhonda Bacher, Kieran McGrail, Martha Campbell-Thompson, Clive Wasserfall, Laura M. Jacobsen, Mark Atkinson, Michael J. Haller, Desmond A. Schatz
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Endocrinology
Subjects:
type 1 diabetes
exocrine pancreas
immunotherapy
thymoglobulin
granulocyte colony stimulating factor
pancreatic alpha-amylase
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2024.1497373/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2024.1497373/full

Similar Items